Isabel Muehlen-Bartmer

1.4k total citations
16 papers, 1.1k citations indexed

About

Isabel Muehlen-Bartmer is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Isabel Muehlen-Bartmer has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Surgery and 2 papers in Molecular Biology. Recurrent topics in Isabel Muehlen-Bartmer's work include Diabetes Management and Research (16 papers), Diabetes Treatment and Management (15 papers) and Pancreatic function and diabetes (8 papers). Isabel Muehlen-Bartmer is often cited by papers focused on Diabetes Management and Research (16 papers), Diabetes Treatment and Management (15 papers) and Pancreatic function and diabetes (8 papers). Isabel Muehlen-Bartmer collaborates with scholars based in United States, Germany and Italy. Isabel Muehlen-Bartmer's co-authors include M. Ziemen, Matthew C. Riddle, Geremia B. Bolli, Philip Home, Richard M. Bergenstal, Marek Wardęcki, Hannele Yki‐Järvinen, Hailing Guo, Emmanuelle Boëlle and Elisabeth Niemoeller and has published in prestigious journals such as Diabetes Care, Diabetes Obesity and Metabolism and Diabetes Technology & Therapeutics.

In The Last Decade

Isabel Muehlen-Bartmer

15 papers receiving 1.1k citations

Peers

Isabel Muehlen-Bartmer
Areti Philotheou South Africa
Birgitte Hylleberg Denmark
G. B. Bolli Italy
Jamie Scism‐Bacon United States
Haysook Choi Canada
Marian Benroubi Greece
Raymond de la Rosa Denmark
Christoph Koenen Denmark
T Tulokas Finland
М. А. Коваренко Russia
Areti Philotheou South Africa
Isabel Muehlen-Bartmer
Citations per year, relative to Isabel Muehlen-Bartmer Isabel Muehlen-Bartmer (= 1×) peers Areti Philotheou

Countries citing papers authored by Isabel Muehlen-Bartmer

Since Specialization
Citations

This map shows the geographic impact of Isabel Muehlen-Bartmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Muehlen-Bartmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Muehlen-Bartmer more than expected).

Fields of papers citing papers by Isabel Muehlen-Bartmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Muehlen-Bartmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Muehlen-Bartmer. The network helps show where Isabel Muehlen-Bartmer may publish in the future.

Co-authorship network of co-authors of Isabel Muehlen-Bartmer

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Muehlen-Bartmer. A scholar is included among the top collaborators of Isabel Muehlen-Bartmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Muehlen-Bartmer. Isabel Muehlen-Bartmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Ritzel, Robert, Stewart B. Harris, Hermes Flórez, et al.. (2018). A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes Care. 41(8). 1672–1680. 41 indexed citations
3.
Bergenstal, Richard M., Timothy S. Bailey, David Rodbard, et al.. (2017). Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 40(4). 554–560. 95 indexed citations
4.
Ritzel, Robert, et al.. (2017). INSULIN GLARGINE 300 U/ML VS. 100 U/ML IN OLDER PEOPLE WITH T2DM: RESULTS FROM A RANDOMIZED TRIAL. Innovation in Aging. 1(suppl_1). 907–907.
5.
Riddle, Matthew C., Geremia B. Bolli, Philip Home, et al.. (2016). Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Diabetes Technology & Therapeutics. 18(4). 252–257. 36 indexed citations
6.
7.
8.
9.
10.
Rabasa‐Lhoret, Rémi, Matthew C. Riddle, Geremia B. Bolli, et al.. (2014). New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM. Canadian Journal of Diabetes. 38(5). S53–S53. 5 indexed citations
11.
Leiter, Lawrence A., Matthew C. Riddle, Geremia B. Bolli, et al.. (2014). Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal + Mealtime Insulin (EDITION 1). Canadian Journal of Diabetes. 38(5). S8–S9. 6 indexed citations
12.
13.
Goldenberg, Ronald, Hannele Yki‐Järvinen, Richard M. Bergenstal, et al.. (2014). Less Nocturnal Hypoglycemia and Weight Gain with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal Insulin with OADs (EDITION 2). Canadian Journal of Diabetes. 38(5). S5–S5. 9 indexed citations
14.
Jeandidier, N., RM Bergenstal, M. Ziemen, et al.. (2014). New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus. 5 indexed citations
15.
Pinget, M., Ronald Goldenberg, Elisabeth Niemoeller, et al.. (2013). Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal ‐P). Diabetes Obesity and Metabolism. 15(11). 1000–1007. 123 indexed citations
16.
Riddle, Matthew C., et al.. (2013). An investigational new insulin glargine U300: glucose control and hypoglycaemia in people with type 2 diabetes using basal and mealtime Insulin (EDITION I). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Areti Philotheou Breakdown of academic impact, for papers by Birgitte Hylleberg Breakdown of academic impact, for papers by G. B. Bolli Breakdown of academic impact, for papers by Jamie Scism‐Bacon Breakdown of academic impact, for papers by Haysook Choi Breakdown of academic impact, for papers by Marian Benroubi Breakdown of academic impact, for papers by Raymond de la Rosa Breakdown of academic impact, for papers by Christoph Koenen Breakdown of academic impact, for papers by T Tulokas Breakdown of academic impact, for papers by М. А. Коваренко
Rankless by CCL
2026